Skip to main content

Table 2 Changes in FLT SUVs, RECIST size measurements, and PSA levels from baseline to 12 weeks were included in Cox proportional hazards regression models to assess association with progression-free survival time

From: FLT PET/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumab

  Predictor C-indexa C-index P value Hazard Ratio HR P value Nb
Traditional markers of response Change PSA 0.72
(0.50 to 0.94)
0.05 2.34
(1.18 to 4.62)
0.01 17 (12)
Change soft tissue tumor size (RECIST) 0.59
(0.54 to 0.63)
< 0.01 1.78
(0.60 to 5.29)
0.30 7 (6)
FLT PET changes in lymphoid organs Change left axillary lymph node SUVmean 0.70
(0.48 to 0.91)
0.07 0.89
(0.43 to 1.84)
0.75 16 (11)
Change spleen SUVmean 0.73
(0.56 to 0.90)
0.01 2.14
(1.11 to 4.12)
0.02 16 (11)
Change bone marrow SUVmean 0.65
(0.41 to 0.89)
0.22 1.94
(0.98 to 3.86)
0.06 17 (12)
FLT PET changes in tumors Change tumor SUVmean 0.83
(0.71 to 0.95)
< 0.01 3.38
(1.01 to 11.28)
0.05 10 (8)
Change tumor SUVtotal 0.69
(0.59 to 0.79)
< 0.01 1.53
(0.76 to 3.10)
0.24 10 (8)
  1. aConcordance index (95% confidence interval shown in parenthesis)
  2. bN = number of patients included in calculation (value in parenthesis is number of patients that were not censored)